See the DrugPatentWatch profile for cosentyx

Cosentyx, also known as secukinumab, is a medication used to treat a variety of conditions including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. As with any medication, there are potential side effects associated with Cosentyx. While most people tolerate the drug well, there are some serious side effects that users should be aware of.

According to the Cosentyx Prescribing Information, serious side effects can include severe infections, allergic reactions, inflammatory bowel disease, and the reactivation of tuberculosis (TB) [2]. Additionally, the drug may increase the risk of certain types of cancer, such as lymphoma and non-melanoma skin cancer [2].

It is important to note that the risk of these serious side effects is relatively low, and the benefits of Cosentyx often outweigh the risks for many people. However, it is crucial that patients discuss these potential side effects with their healthcare provider before starting the medication.

Another important consideration is the cost of Cosentyx. As a specialty medication, Cosentyx can be quite expensive, with a list price of around $15,000 per year [3]. However, there are resources available to help patients access the medication at a more affordable price. For example, Novartis, the manufacturer of Cosentyx, offers a patient assistance program called Novartis Patient Assistance Foundation, Inc. (NPAF) [4].

In summary, while Cosentyx can be an effective treatment option for a variety of conditions, it is important for patients to be aware of the potential serious side effects associated with the medication. Patients should discuss these risks with their healthcare provider and explore resources for affordable access to the medication.

Sources:

1. Cosentyx (secukinumab) [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2021. Available from: <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>.
2. Cosentyx (secukinumab) [Highlights of Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2021. Available from: <https://www.novartis.us/sites/www.novartis.us/files/cosentyx-highlights-of-prescribing-information.pdf>.
3. DrugPatentWatch. Cosentyx (secukinumab) [Patent Information]. Available from: <https://www.drugpatentwatch.com/patent/cosentyx-secukinumab>.
4. Novartis Patient Assistance Foundation, Inc. (NPAF). Cosentyx (secukinumab) [Patient Assistance Program]. Available from: <https://www.novartis.us/our-work/access-medicine/patient-assistance-foundation>.